孕前和孕期人工加糖饮料的消费及其与不良妊娠结局的关系：澳大利亚妇女健康纵向研究的结果

IF 7.4 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-08-21 DOI:10.1016/j.diabres.2025.112422

Bereket Gebremichael , Mumtaz Begum , Tina Bianco-Miotto , Shao Jia Zhou , Zohra S. Lassi

{"title":"孕前和孕期人工加糖饮料的消费及其与不良妊娠结局的关系：澳大利亚妇女健康纵向研究的结果","authors":"Bereket Gebremichael , Mumtaz Begum , Tina Bianco-Miotto , Shao Jia Zhou , Zohra S. Lassi","doi":"10.1016/j.diabres.2025.112422","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><div>Exposure to artificial sweeteners has been linked to adverse health outcomes. We aimed to examine the association between preconception and pregnancy artificially sweetened beverage (ASB) consumption and adverse pregnancy outcomes.</div></div><div><h3>Methods</h3><div>We analysed data from 3,653 women from the Australian Longitudinal Study on Women’s Health (ALSWH). A generalized linear mixed model and augmented inverse probability weighting estimator were used to estimate the relative risk and average treatment effect (ATE), respectively.</div></div><div><h3>Results</h3><div>The incidence of gestational diabetes mellitus (GDM), hypertensive disorder of pregnancy (HDP), and preterm birth (PTB) in the preconception exposure group was 9.1 %, 6.7 %, and 4.3 %, while it was 8.6 %, 7.5 %, and 4.0 % in the pregnancy exposure group, respectively. The adjusted relative risk (aRR) of frequent ASB consumption (≥5 drinks/week) during pregnancy compared with none were 1.88 (95 % CI: 1.12–3.14) for GDM, 1.59 (95 % CI: 0.86–2.93) for HDP, and 1.22 (95 % CI: 0.36–3.99) for PTB. The ATE of frequent ASB intake during pregnancy compared to none was 0.06 (95 % CI: 0.01–0.11). The association between preconception ASB exposure and all outcomes remain uncertain.</div></div><div><h3>Conclusion</h3><div>Frequent ASB consumption during pregnancy is associated with a higher risk of GDM, while its association with HDP and PTB remains inconclusive.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"227 ","pages":"Article 112422"},"PeriodicalIF":7.4000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preconception and pregnancy artificially sweetened beverage consumption and its association with adverse pregnancy outcomes: findings from the Australian longitudinal study on women’s health\",\"authors\":\"Bereket Gebremichael , Mumtaz Begum , Tina Bianco-Miotto , Shao Jia Zhou , Zohra S. Lassi\",\"doi\":\"10.1016/j.diabres.2025.112422\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and aim</h3><div>Exposure to artificial sweeteners has been linked to adverse health outcomes. We aimed to examine the association between preconception and pregnancy artificially sweetened beverage (ASB) consumption and adverse pregnancy outcomes.</div></div><div><h3>Methods</h3><div>We analysed data from 3,653 women from the Australian Longitudinal Study on Women’s Health (ALSWH). A generalized linear mixed model and augmented inverse probability weighting estimator were used to estimate the relative risk and average treatment effect (ATE), respectively.</div></div><div><h3>Results</h3><div>The incidence of gestational diabetes mellitus (GDM), hypertensive disorder of pregnancy (HDP), and preterm birth (PTB) in the preconception exposure group was 9.1 %, 6.7 %, and 4.3 %, while it was 8.6 %, 7.5 %, and 4.0 % in the pregnancy exposure group, respectively. The adjusted relative risk (aRR) of frequent ASB consumption (≥5 drinks/week) during pregnancy compared with none were 1.88 (95 % CI: 1.12–3.14) for GDM, 1.59 (95 % CI: 0.86–2.93) for HDP, and 1.22 (95 % CI: 0.36–3.99) for PTB. The ATE of frequent ASB intake during pregnancy compared to none was 0.06 (95 % CI: 0.01–0.11). The association between preconception ASB exposure and all outcomes remain uncertain.</div></div><div><h3>Conclusion</h3><div>Frequent ASB consumption during pregnancy is associated with a higher risk of GDM, while its association with HDP and PTB remains inconclusive.</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"227 \",\"pages\":\"Article 112422\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S016882272500436X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S016882272500436X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的接触人造甜味剂与不良健康结果有关。我们的目的是检查孕前和妊娠人工加糖饮料（ASB）消费和不良妊娠结局之间的关系。方法：我们分析了来自澳大利亚妇女健康纵向研究（ALSWH）的3,653名妇女的数据。使用广义线性混合模型和增广逆概率加权估计器分别估计相对风险和平均治疗效果（ATE）。结果孕前暴露组妊娠期糖尿病（GDM）、妊娠期高血压病（HDP）和早产（PTB）的发生率分别为9.1%、6.7%和4.3%，妊娠暴露组分别为8.6%、7.5%和4.0%。妊娠期间频繁饮用ASB（≥5杯/周）与不饮用ASB的校正相对危险度（aRR）为：GDM为1.88 (95% CI: 1.12-3.14)， HDP为1.59 (95% CI: 0.86-2.93)， PTB为1.22 （95% CI: 0.36-3.99）。妊娠期间频繁摄入ASB与不摄入ASB的ATE为0.06 （95% CI: 0.01-0.11）。孕前ASB暴露与所有结果之间的关系仍不确定。结论妊娠期频繁食用ASB与GDM风险升高相关，但与HDP和PTB的相关性尚不明确。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Preconception and pregnancy artificially sweetened beverage consumption and its association with adverse pregnancy outcomes: findings from the Australian longitudinal study on women’s health

Background and aim

Exposure to artificial sweeteners has been linked to adverse health outcomes. We aimed to examine the association between preconception and pregnancy artificially sweetened beverage (ASB) consumption and adverse pregnancy outcomes.

Methods

We analysed data from 3,653 women from the Australian Longitudinal Study on Women’s Health (ALSWH). A generalized linear mixed model and augmented inverse probability weighting estimator were used to estimate the relative risk and average treatment effect (ATE), respectively.

Results

The incidence of gestational diabetes mellitus (GDM), hypertensive disorder of pregnancy (HDP), and preterm birth (PTB) in the preconception exposure group was 9.1 %, 6.7 %, and 4.3 %, while it was 8.6 %, 7.5 %, and 4.0 % in the pregnancy exposure group, respectively. The adjusted relative risk (aRR) of frequent ASB consumption (≥5 drinks/week) during pregnancy compared with none were 1.88 (95 % CI: 1.12–3.14) for GDM, 1.59 (95 % CI: 0.86–2.93) for HDP, and 1.22 (95 % CI: 0.36–3.99) for PTB. The ATE of frequent ASB intake during pregnancy compared to none was 0.06 (95 % CI: 0.01–0.11). The association between preconception ASB exposure and all outcomes remain uncertain.

Conclusion

Frequent ASB consumption during pregnancy is associated with a higher risk of GDM, while its association with HDP and PTB remains inconclusive.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.